K
Ke Fei
Researcher at Tongji University
Publications - 66
Citations - 2663
Ke Fei is an academic researcher from Tongji University. The author has contributed to research in topics: Lung cancer & Adenocarcinoma. The author has an hindex of 22, co-authored 64 publications receiving 2031 citations. Previous affiliations of Ke Fei include University of Colorado Boulder.
Papers
More filters
Journal ArticleDOI
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Wen-Zhao Zhong,Qun Wang,Weimin Mao,Song-Tao Xu,Lin Wu,Yi Shen,Yongyu Liu,Chun Chen,Ying Cheng,Lin Xu,Jun Wang,Ke Fei,Xiaofei Li,Jian Li,Cheng Huang,Zhidong Liu,Shun Xu,Ke-Neng Chen,Shidong Xu,Lunxu Liu,Ping Yu,Bu-Hai Wang,H. Ma,Hong-Hong Yan,Xue-Ning Yang,Qing Zhou,Yi-Long Wu,Siyu Wang,Jian Hu,Wei Liu,Wei Li,Jianhua Shi +31 more
TL;DR: Adjuvant gefitinib led to significantly longer disease-free survival compared with that for vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant NSCLC.
Journal ArticleDOI
Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study.
Chenyang Dai,Jianfei Shen,Yijiu Ren,Shengyi Zhong,Hui Zheng,Jiaxi He,Dong Xie,Ke Fei,Wenhua Liang,Gening Jiang,Ping Yang,René Horsleben Petersen,Calvin S.H. Ng,Chia-Chuan Liu,Gaetano Rocco,Alessandro Brunelli,Yaxing Shen,Chang Chen,Jianxing He +18 more
TL;DR: Lobectomy showed better survival than sublobar resection for patients with NSCLC ≤ 1 cm and > 1 to 2 cm, whereas surgeons could rely on surgical skills and the patient profile to decide between segmentectomy and wedge resection For patients in whom lobectomy is unsuitable, segmentectomy should be recommended.
Journal ArticleDOI
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
Bing Li,Shengxiang Ren,Xuefei Li,Yongsheng Wang,David Garfield,Songwen Zhou,Xiaoxia Chen,Chunxia Su,Mo Chen,Peng Kuang,Guanghui Gao,Yayi He,Lihong Fan,Ke Fei,Caicun Zhou,Gerald Schmit-Bindert +15 more
TL;DR: In this article, miR-21 was found to be involved in acquired resistance of EGFR-TKI in NSCLC, which is mediated by down-regulating PTEN and PDCD4 and activating PI3K/Akt pathway.
Journal ArticleDOI
Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR -mutant non-small cell lung cancer
Ningning Cheng,Weijing Cai,Shengxiang Ren,Xuefei Li,Qi Wang,Hui Pan,Mingchuan Zhao,Jiayu Li,Yishi Zhang,Chao Zhao,Xiaoxia Chen,Ke Fei,Caicun Zhou,Fred R. Hirsch +13 more
TL;DR: The influence of over-expression of UCA1 on PFS for patients with acquired resistance to EGFR-TKIs was from the subgroup with non-T790M mutation, and UCA2 knockdown restored gefitinib sensitivity and inhibited the activation of the AKT/mTOR pathway and epithelial-mesenchymal transition (EMT).
Journal ArticleDOI
Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways
Xiaofeng Chen,Huijun Zhang,Hai-Bing Wang,Jun Zhu,Wenyong Zhou,Hui Zhang,Mingchuan Zhao,Jin-Mei Su,Wen Gao,Lei Zhang,Ke Fei,Hong-Tao Zhang,Heyong Wang +12 more
TL;DR: Investigation of PI3K/Akt and MAPK/Erk1/2 signaling pathways involved in EMT in the human lung cancer A549 cells showed that after treated with TGF-β1 for 48 h, A549 Cells displayed more fibroblast-like shape, lost epithelial marker E-cadherin and increased mesenchymal markers Vimentin and Fibronectin.